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Abstract 
Objectives
Charcot-Marie-tooth disease type 4 (CMT4D) is an autosomal 
recessive form of Charcot-Marie-tooth disease with an earlier age of 
onset and greater severity, compared to other types of this disease. 
CMT4C and CMT4D are the most prevalent subtypes in Mediterranean 
countries due to the higher rate of consanguineous marriage. In this 
study, we aimed to identify p.R148X mutation in NDRG1 gene and 
p.R1109X mutation in SH3TC2 gene (responsible for CMT4D and 
CMT4C, respectively) and to investigate other possible nucleotide 
changes in exon 14 of SH3TC2 gene and exon 7 of NDRG1 gene in 
an Iranian population.
Materials & Methods
A total of 24 CMT4D patients, who were referred to Iran Special 
Medical Center, were clinically and electrophysiologically evaluated 
in this study. DNA was extracted from the patients’ blood samples. 
Next, polymerase chain reaction (PCR) assay was carried out, and the 
products were sequenced and analyzed in FinchTV software.
Results
None of the target mutations were found in this study. Sequencing of 
SH3TC2 gene showed SNP rs1025476 (g.57975C>T) in 21 (87.5%) 
patients, including 7 homozygous and 14 heterozygous individuals.
Conclusion
Despite the high rate of mutations in some populations, it seems 
that they are very rare in Iranian CMT4D patients. Regarding the 
association of SNP rs1025476 with CMT4D, further assessments are 
needed to reach a better understanding of genetic markers and their 
genetic features and to propose better diagnostic and treatment plans 
for the Iranian population. 
Keywords: SH3TC2 gene; NDRG1 gene; CMT4D; Charcot-Marie-
tooth disease; Iran
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Introduction 
Charcot-Marie-tooth disease (CMTD) is recognized 
as the most common inherited neuromuscular 
disorder. It is a gradually progressive disease 
with an approximate prevalence of 1/2500 people 
(1). Symptoms of this disease include muscle 
weakness and atrophy, which may appear from 
the first to the third decade of life. Genetically, 
it is a heterogeneous disease with an autosomal 
dominant, autosomal recessive (AR), or X-linked 
inheritance (2). 
In recent decades, classification of CMTD has 
become more complex (3), and its inheritance 
modes (2, 4, 5) and involved nerves vary in each 
type. Responsible mutations have been identified 
in more than 80 genes. Generally, different 
mutations cause different modes of inheritance (6-
8). Charcot-Marie-tooth disease type 4 (CMT4D) is 
an AR form of demyelinating CMTD. This disease 
is characterized by an early onset, usually before 
the age of 2-3 years, and rapid clinical progression, 
which leads to more distal limb deformities (9, 10).
In recent studies, it has been suggested that 
mutations in SH3TC2 gene, which are responsible 
for CMT4C, are the most common contributing 
factors for CMT4D not only in the Mediterranean 
region, but also in European and North American 
countries (9). SH3TC4 gene, also known as 
KIAA1985 gene, encodes a protein, which is 
expressed in the peripheral nerves of Schwann 
cells (11, 12). This protein is required for proper 
myelination and integrity of the node of Ranvier 
in the peripheral nervous system (6). According to 
recent studies, lack of SH3TC1 gene in recycling 
endosomes is an underlying molecular defect, 
leading to CMT4C (13). This gene includes 17 
encoding exons and is located on chromosome 5 
(5q32). It is clear that a defect in this gene causes 
myelination defects. 
NDRG1 gene mutation leads to the development 
of hereditary motor and sensory neuropathy 
Lom type, also known as CMT4D (14). CMT4D 
is characterized by Schwann cell dysfunction, 
associated with early and severe axonal loss due 
to axon-glial interaction failure (9, 14). Recent 
studies have concluded that impaired Schwann cell 
trafficking fails to meet the considerable demands 
of nerve growth and may be involved in the 
pathogenetic mechanism of NDRG1 deficiency. 
One of the mutations is located on codon 148 of 
NDRG1 gene (15, 16). NDRG1 gene, which is 
ubiquitously expressed, contributes to growth 
arrest, cell differentiation, and possibly signaling 
protein shuttling between the cytoplasm and the 
nucleus. This gene is located on chromosome 
8q24.3, with a high level of expression in Schwann 
cells (14).
In the present study, we aimed to investigate 
CMT4C and CMT4D with an AR mode of 
inheritance, which show greater severity and 
earlier age of onset, compared to other types of 
CMTD (9, 17). Different mutations are responsible 
for CMT4D. Generally, ten different subclasses 
have been recognized so far, each responsible for 
CMT4A–J (9). Since ARCMT is more frequent 
in countries with a high rate of consanguineous 
marriage (17), we aimed to analyze two mutations 
of p.R148X in NDRG1 gene and p.R1109X in 
SH3TC2 gene, which can both create stop codons, 
responsible for CMT4D and CMT4C, respectively. 
Considering the higher rate of consanguineous 
marriage in some regions of Iran, we may assume 
that these mutations play a significant role in this 
population. 
Early onset of CMTD subtypes and their severe 
phenotypes, which are associated with severe 
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polyneuropathy and specific deformations, 
encouraged us to collect more information about 
these diseases in the Iranian population. In this 
study, we aimed to investigate the presence of 
p.R148X mutation in NDRG1 gene and p.R1109X 
mutation in SH3TC2 gene and to identify other 
possible mutations and polymorphisms in 24 
Iranian CMT4D patients, who were referred to Iran 
Special Medical Center. (No 4, Ostadnejatolahi St. 
Tehran, Iran.)
Materials &Methods
In this survey, a total of 24 patients (14 males 
and 10 females; mean age=8.7 years), who were 
referred to a medical center, were studied under the 
supervision of neurologists and clinical geneticists 
for accurate diagnosis of CMT4D. Most patients 
presented with early-onset demyelinating 
neuropathy, distal muscular hypotrophy, scoliosis, 
and other basic features of the disease. No mutation 
in previously screened GDAP1 gene, which is 
another responsible gene for CMT4D (9), was 
found in the patients. Both parents of all probands 
were healthy, and informed consent was obtained 
from the parents or guardians of the patients. 
A blood sample (2 cc) was collected from each 
patient and preserved in a falcon tube, containing 
EDTA at -20°C until DNA extraction. Genomic 
DNA was extracted using Genpajoohan DNA 
Extraction Kit (Iran) and stored at -20°C. Target 
DNA fragments of NDRG1 exon 7 and SH3TC2 
exon 14 were amplified by polymerase chain 
reaction (PCR) assay with forward and reverse 
primers (primer sequences and PCR conditions are 
available upon request). Appropriate synthesis of 
PCR products was evaluated using 1.5% Agarose 
gel electrophoresis. 
The search for mutations (p.R148X mutation in 
NDRG1 gene and p.R1109X mutation in SH3TC2 
gene) was conducted via Sanger sequencing of PCR 
products, using the ABI3700 tool (Kosar Kavosh 
Fanavaron Co., Iran). FinchTV software was 
also used for analyzing the sequences in order to 
identify mutations. The sequences were blasted in 
NCBI website (http://www.ncbi.nlm.nih.gov/blast) 
and compared with normal sequences. The length 
of PCR products for analyzing exon 14 of SH3TC2 
gene was 331 bp. To ensure the authenticity of the 
products, they were compared with a 100-bp DNA 
ladder via 1.5% Agarose gel electrophoresis. In 
addition, the length of PCR product was 170 bp for 
exon 7 of NDRG1 gene, which was compared with 
the 50-bp DNA ladder.
Results
Sequence analysis indicated that p.R148X 
mutation of NDRG1 gene and p.R1109X mutation 
of SH3TC2 gene (both responsible for CMT4D) 
were not present in the target regions and that the 
sequences were normal. Based on the sequence 
analysis of SH3TC2 gene (exon 14), 21 out 
of 24 probands (87.5%) showed g.57975C>T 
variant (c.3327+70C>T), including 14 (58%) 
heterozygous and 7 (29%) homozygous individuals 
for this nucleotide mutation (Figure 1). The three 
remaining patients showed normal sequences. 
Analysis of NDRG1 sequences (exon 7) indicated 
that all 24 probands had normal sequences in the 
evaluated region and that no nucleotide changes 
were observed. Some sequence analyses were 
performed for assessment by reverse primers. To 
ensure the results of sequencing, four samples were 
randomly considered for assessment by reverse 
primers (two samples for SH3TC2 gene and two 
samples for NDRG1 gene). The results showed 
the authenticity of previous results obtained from 
analyses using forward primers.
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Discussion
According to previous studies, AR-CMTD can be 
found in people of all races. As multiple studies 
have indicated, the prevalence of mutations varies 
in different populations. It is noticeable that in 
Western countries, the prevalence of AR-CMTD 
is significantly lower than the dominant form of 
CMTD (12). Evidence suggests that the prevalence 
of AR-CMTD is about 10% in Europe and 30-50% 
in Mediterranean countries (18).
According to a previous study on recessive CMTD, 
conducted in 2014 in Germany, involvement 
of genes, such as GDAP, HINT1, SH3TC2, and 
NDRG1, was estimated at 10.9%, 10.3%, 7.5%, 
and 6.3%, respectively (19). In a previous study 
on a gypsy population, involvement of these genes, 
including p.R148X mutation in NDRG1 gene, was 
reported in nearly 4.46% of AR-CMTD cases 
(19). On the other hand, in a study on another 
gypsy population in Bulgaria, the high frequency 
of p.R148x mutation was reported, and mutation 
carriers accounted for 10-16% of the population 
(20). 
The presence of p.R1109X mutation in SH3TC2 
gene has not been examined separately, and different 
results have been reported regarding the overall 
contribution of this mutation. CMT4D (mutation 
in NDRG1 gene), a common form of AR-CMTD in 
gypsy populations, has been reported in European 
countries. It is the most frequent  peripheral 
Figure 1. (a) Homozygous g.57975C>T variant in exon 14 of SH3TC2 gene and (b) heterozygous g.57975C>T variant of SH3TC2 gene
neuropathy among Serbian gypsies (21, 22), 
whereas in Spain, the prevalence rate is different. 
In addition, CMT4C (mutation in SH3TC2 gene) 
is the most common form of CMT4D in the gypsy 
population of Spain, followed by CMT4G and 
CMT4D (23). 
In another study from Spain on 29 gypsy individuals 
with recessive CMT4D, the prevalence of SH3TC2 
gene mutation (CMT4C) was 57.14%, the 
prevalence of HK1 gene mutation (CMT4G) was 
25%, and the prevalence of CMT4D was 17.86% 
(21). Furthermore, a study from South of Italy on 
197 CMTD patients revealed that the prevalence 
of SH3TC2 gene was only 2% in the general 
population in the same period (24). Moreover, a 
study performed in 2016 in Germany showed that 
the overall prevalence of SH3TC2 gene was 2.7% 
in patients with demyelinating CMTD (25).
Although the rate of these mutations is very low 
in most countries, a high rate has been reported in 
gypsy populations, as mentioned earlier, which may 
be attributed to their specific features and genetic 
differences (20, 26, 27). According to previous 
studies, the gypsy population was influenced by 
the bottleneck effect due to the migration of their 
ancestors from India to Europe. Also, research on 
genetic markers show that gypsies migrated from 
India to countries, such as Pakistan, Iran, Turkey, 
South Armenia, and Europe (28); therefore, genetic 
merging may have occurred in some traits and 
97
Investigation of Mutations in Exon 14 of SH3TC2 Gene and Exon 7 of NDRG1 Gene in Iranian Charcot
Iran J Child Neurol. Spring  2020 Vol. 14 No. 2
genes in these countries. 
Evidence suggests that pathogenic mutations 
responsible for AR myasthenic syndromes were 
inherited from the common ancestry history of 
gypsy, Indian, and Pakistani populations (29). 
Therefore, the incidence of these mutations in the 
Iranian population is highly expected considering 
the prevalence of consanguineous marriage in 
some parts of Iran. Based on studies from Turkey 
and Spain, one of the target mutations in our study 
(p.R1109X) had a very distant ancestral origin; 
this finding shows that mutations occurred in new 
generations. Moreover, estimation of allelic age 
indicates that p.R1109X mutation in SH3TC2 gene 
was related to the bottleneck effect and probably 
occurred 225 years ago (between the late 18th 
century and early 19th century) (21). According 
to previous studies, these mutations mostly 
occurred in isolated populations with a high rate of 
consanguineous marriage. 
Despite the presence of these mutations in 
other populations from some Mediterranean 
and European countries, such as Spain and 
Czechoslovakia, no mutations were found in our 
study; accordingly, the studied mutations are 
very rare in non-specific populations. Differences 
between the findings of our study and studies on 
other populations can be attributed to differences 
in the structure, ethnic background, and origin of 
Iranian population. Considering the limitations 
in the availability of CMT4 probands, lack of the 
studied mutations in our population may indicate 
that other mutations in SH3TC2 and NDRG1 genes 
or other causative genes are involved in CMT4C 
and CMT4D due to the heterogenic features of the 
disease.
Analysis of the intronic region near exon 14 
of SH3TC2 gene indicated rs1025476 SNP 
(g.57975C>T). It should be noted that this SNP was 
found in a study on a Turkish control population 
(30). Moreover, since this SNP was found in the 
majority of proband genes, this mutation may be 
one of the genetic characteristics of the studied 
population; such findings can be useful for a better 
understanding of the genomic features of Iranian 
population. To clarify the association between this 
SNP and CMTD, further assessments using case-
control studies with a higher number of patients 
and greater funding are necessary to overcome the 
limitations of previous studies. 
In Conclusion, By applying more comprehensive 
methods, such as next generation sequencing, in 
future studies, we can have a more comprehensive 
view about this issue. Overall, our findings 
contribute to the available genetic data regarding 
CMT4D in the Iranian population. Further genetic 
analysis can provide a better diagnostic approach 
for this disease through identification of rare 
or common genetic features in each specific 
population.
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